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Abstract Germline mutations in BRCA1/BRCA2 signifi-
cantly increase the risk of breast and ovarian cancer in
women. This case report describes a BRCA1 germline
mutation identified in a woman with stage IV epithelial
ovarian cancer and the provision of genetic counseling
about BRCA1-associated breast cancer risk in the three
years following diagnosis. The report centers on the pa-
tient’s enquiry about risk-reducing breast surgery. We
focus on the challenges for health professionals and pa-
tients in understanding and balancing the risks and ben-
efits of major prophylactic surgery in the context of a
potentially life-limiting cancer diagnosis. Breast cancer
risk management in BRCA1/BRCA2 carriers with ad-
vanced ovarian cancer is an under-explored area of ge-
netic counseling research. This article includes a case
report, a review of the relevant literature and considers
some implications for practice.
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Introduction
BRCA1/BRCA2-associated cancer risk management includes
increased cancer surveillance and risk reduction strategies. For
breast cancer risk, additional screening using mammography
and MRI is recommended with the aim of detecting cancer at
an early stage (Kriege et al. 2004). The most significant breast
cancer risk reduction strategy involves bilateral mastectomy,
usually combined with breast reconstruction. Risk reducing
surgery is usually most relevant between approximately ages
30–60, during the years when relative breast cancer risk is
high and the risk-benefit balance is more likely to be
favourable. In countries with BRCA1 and BRCA2 manage-
ment guidelines, discussion with women on the risks as well
as the potential benefits associated with surgery is recom-
mended (Easton et al. 2015). A woman’s age and general
health have a critical impact on these risks.
Risk reduction strategies are most relevant to women iden-
tified as carrying a BRCA1 or BRCA2 mutation who have not
yet developed cancer and the role of risk-reducing surgery in
the management of hereditary breast and ovarian cancer is
already well established (Hartmann and Lindor 2015).
However, identification of a hereditary BRCA1/BRCA2muta-
tion in a family is often via initial diagnostic testing in an
individual with cancer. The benefits of identifying a germline
mutation soon after diagnosis can have implications for early
treatment decisions and access tomore effective therapies, e.g.
poly(adenosine diphosphate ribose) polymerase (PARP) in-
hibitors (Konecny and Kristeleit 2016).
In the UK, as in other countries, there is movement towards
offering more women with non-mucinous epithelial ovarian
cancer genetic testing of BRCA1 and BRCA2, irrespective of
family history (George 2015). In our center, genetic testing of
BRCA1 and BRCA2 is automatically offered to every woman
with epithelial ovarian cancer diagnosed below age 70 years.
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This is based on research showing that 12% of women diag-
nosed below age 70 years in our region have a germline mu-
tation, without taking family history into account
(Plaskocinska et al. 2016).
This type of unselected genetic testing in newly diagnosed
women with epithelial ovarian cancer is leading to more fam-
ilies without a strong history of breast cancer being found with
germline BRCA1/BRCA2 mutations. In these families, there
may not have been any prior anticipation of an increased
breast cancer risk, given the absence of any family history of
breast cancer. Women with ovarian cancer in whom the path-
ogenic variant has been identified may be adjusting to infor-
mation about a high breast cancer risk for themselves and
other family members at a vulnerable time, if this comes short-
ly after an ovarian cancer diagnosis.
There is evidence that genetic testing soon after ovarian
cancer diagnosis does not add to the negative psychological
response caused by the cancer diagnosis itself, but that finding
out about BRCA1/BRCA2 carrier status may lead to a slight
increase in the psychological burden at that time
(Plaskocinska et al. 2016). However, little is known about
how women identified as carrying a BRCA1/BRCA2mutation
after an ovarian cancer diagnosis adjust to and view their
breast cancer risk. The experience within our clinical genetics
service is that most women accept the offer of referral for
increased breast surveillance and few request detailed infor-
mation on risk-reducing breast surgery. Risk reducing surgery
is generally not considered as beneficial in the initial years
after stage III or IVovarian cancer diagnosis, due to the focus
on treatment, uncertainty about recurrence and prognosis.
However, breast cancer risk reduction is a valid issue for
women to raise and awareness of risk-reducing surgery has
increased in recent years due to high-profile publicity (Evans
et al. 2014). Information about risk-reducing breast surgery is
also provided by charities aimed at supporting and informing
women after an ovarian cancer diagnosis. Increased awareness
of risk reducing surgical options is likely to increase the num-
ber of women at high risk of breast cancer asking about the
potential benefits this can bring and there is some evidence of
this happening in recent years (Evans et al. 2015).
Case Report: Background
This case describes a 54 year old diagnosed with stage IV high
grade serous ovarian cancer. The patient provided adequate
family history information, reporting relatively few cancers
in a large family, except for suspected ovarian cancer in her
paternal grandmother (unconfirmed). Genetic testing was car-
ried out via the Genetic Testing in Epithelial Ovarian Cancer
study (Plaskocinska et al. 2016). This study offered BRCA1
and BRCA2 testing via telephone contact with the study co-
ordinator but no formal pre-test genetic counseling to women
with a recent diagnosis of epithelial ovarian cancer. Genetic
testing revealed a frameshift BRCA1 mutation, previously re-
ported in the literature as a pathogenic variant causing a high
risk of breast and ovarian cancer. The patient was referred for
genetic counseling, at which point she asked about the impli-
cations of the BRCA1 mutation on ovarian cancer prognosis,
breast cancer risk management and the risk for her first degree
relatives. Genetic counselor-initiated discussion included the
broader implications for relatives and the psychosocial impact
of learning about BRCA1 mutation status. The patient had an
excellent partial response to neo-adjuvant chemotherapy
(Carboplatin and Paclitaxel) with no residual disease after
total abdominal hysterectomy and no evidence of disease after
six months of adjuvant chemotherapy. The patient was inter-
ested in accessing risk reducing breast surgery and after an
initial discussion 17 months post ovarian cancer diagnosis,
she requested follow up in the genetics clinic 2 years and
10 months post diagnosis for a further discussion to weigh
up the risks and potential benefits. The patient articulated
her motivations for asking about risk reducing breast surgery
as wanting to stay free from cancer for as many years as
possible. She was already familiar with information about
ovarian cancer prognosis in general and her own excellent
response to treatment from appointments with her oncology
team.
Breast Cancer Risk in BRCA1/BRCA2 Carriers
after Ovarian Cancer Diagnosis
A small number of studies have indicated that breast cancer
risk is lower inBRCA1/BRCA2mutation carriers after an ovar-
ian cancer diagnosis, compared to unaffectedmutation carriers
(Domchek et al. 2013; Gangi et al. 2014; McGee et al. 2017;
Vencken et al. 2013). However, data on breast cancer risk in
BRCA1/BRCA2 carriers after ovarian cancer are limited as a
result of the poor overall survival. As part of the study by
Vencken et al., 79 women with BRCA1/BRCA2-associated
(mostly advanced stage) ovarian cancer but no personal histo-
ry of breast cancer were followed over 10 years. The women
were calculated as having a lower 5-year risk of primary breast
cancer of 6%, compared to 16% for the unaffected mutation
carrier controls. The 10-year breast cancer risk in women with
BRCA1/BRCA2-associated ovarian cancer was 11%, com-
pared to 28% in the control group (mortality rates at five and
ten years were 33% and 61%, respectively).
Similarly, Domchek et al. (2013) studied 164 BRCA1/
BRCA2 mutation carriers with epithelial ovarian cancer to
assess metachronous breast cancer risk. Among the 164 par-
ticipants, 18 breast cancers were diagnosed, but no breast can-
cer related deaths occurred (Domchek et al. 2013). Based on
their five and ten year figures for breast cancer free survival
and overall survival after ovarian cancer, the authors suggest
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non-surgical management of breast cancer risk in women with
a BRCA1/BRCA2-associated ovarian cancer. McGee et al.
(2017) also found a lower than expected breast cancer inci-
dence in their study cohort of 509 BRCA1/BRCA2 mutation
carriers followed up to 20 years (mean 6.9 years) after ovarian
cancer diagnosis. During the follow up period, 203 women
died of ovarian cancer, but only 20 women developed breast
cancer. Of the four cancer deaths amongst these 20 women,
two died from breast cancer and two from recurrent ovarian
cancer. The aim of the study by McGee et al. was to estimate
breast cancer risk and all-cause mortality after ovarian cancer
in BRCA1/BRCA2 carriers in order to simulate the impact of
providing MRI or risk-reducing mastectomy subsequent to
ovarian cancer diagnosis. Their simulation reported a less than
1% reduction in the chance of dying (of all causes) before age
80 due to breast MRI screening and a less than 2% reduction
due to risk-reducing mastectomy. In the absence of a consen-
sus on the minimum expected benefit to validate MRI or mas-
tectomy, the authors suggest based on their data that these
options should be offered to all BRCA1/BRCA2 carriers with
Stage I/II ovarian cancer, but only offered to those with Stage
III/IV ovarian cancer diagnosed before age 50 or at least
10 years post ovarian cancer diagnosis without recurrence.
Further evidence of a reduced breast cancer risk in BRCA1/
BRCA2 carriers after ovarian cancer compared to controls was
provided by a database review conducted by Gangi et al.
(2014). Of 135 mutation carriers followed up between 1998
and 2012, 12 (8.9%) developed breast cancer and seven of
these tumors were detected at mammography. All were
early-stage breast cancer diagnoses (stages 0-II). At a median
follow-up of 6.3 years, four of the 12 women (33.3%) died of
recurrent ovarian cancer after a diagnosis of breast cancer,
whilst overall survival of the 135 women was 17% (Gangi
et al. 2014).
The majority of epithelial ovarian cancers initially respond
well to platinum-based chemotherapy, but long term survival
is limited by recurrence of tumor cells which develop drug
resistance (Bookman et al. 2009). International consensus
guidelines state that the mainstay of ovarian cancer treatment
involves surgery aiming at complete resection, followed by
platinum and taxane-based chemotherapy (du Bois et al.
2009). The most important prognostic factor appears to be
tumor burden at diagnosis, classified by FIGO stage I-IV,
followed by completeness of cytoreductive surgery, exempli-
fied in a study of 3126 women with ovarian cancer where a
subset of 63women had FIGO stage IVovarian cancer with no
macroscopic residual tumor after surgery (du Bois et al. 2009).
Approximately 25% of women in this subset had progression-
free survival five years later. A similar likelihood of
progression-free survival was shown after five years in a large
cohort of women with FIGO stage III or IVepithelial ovarian
cancer (Bookman et al. 2009) but these studies did not take
BRCA1/BRCA2 mutation status into account.
Germline BRCA1/BRCA2Mutations and Ovarian
Cancer Treatment Outcomes
Germline BRCA1/BRCA2 mutation status impacts on
treatment outcomes in ovarian cancer, as shown in a study
of 1001 women with epithelial ovarian cancer which
found that 14.1% carried a germline mutation in BRCA1
or BRCA2 (Alsop et al. 2012). In this study, mutation
carriers were more often diagnosed at an advanced stage
of disease, but also had better treatment outcomes; after
adjustment for age, stage and extent of surgical resection,
BRCA1 and BRCA2 mutation carriers had improved 5-
year progression-free survival and overall survival. The
best 5-year progression-free survival of approximately
50% was observed in women with a germline BRCA1
mutation with no residual tumor after surgery. A favorable
effect on 5-year survival in BRCA1/BRCA2 carriers with
ovarian cancers was also seen in a pooled analysis of 26
observational ovarian cancer survival studies (Bolton
et al. 2012). However, other studies have produced con-
flicting results, indicating no advantage in 5-year overall
survival in BRCA1 carriers (Yang et al. 2011). There is
evidence suggesting that any short to medium term sur-
vival advantage may not translate into significantly higher
long-term survival (Candido-dos-Reis et al. 2015;McLaughlin
et al. 2012), although substantial data on this are lacking.
Case Report: Genetic Counseling Provision
We provided an approximate 5-year risk of breast cancer as
10%, based on her current age and BRCA1 status (Mavaddat
et al. 2013). Based on individual factors, we then discussed
how her absolute risk of breast cancer over the five years
following diagnosis may be lower than this, due to evidence
suggesting a reduction in breast cancer risk after ovarian can-
cer diagnosis in BRCA1 carriers. We also mentioned a poten-
tially protective cytotoxic effect of chemotherapy on any early
breast cancer cells. We were unaware if the patient had been
recruited to the treatment or control arm of a PARP inhibitor
trial, but the possibility of a similar cytotoxic impact on very
early breast cancer from PARP inhibitors was highlighted.
The patient was somewhat reassured by having regular chest
CT scans arranged for all participants of the PARP inhibitor
trial, as this might increase the chance of picking up a breast
tumor at an early stage, alongside annual breast screening.
We discussed the associated risks and benefits of risk re-
ducing breast surgery and reconstruction. Information on risks
included how surgery may not always go as planned, how
women are not always pleased with the look and feel of re-
constructed breasts and there can be problems with infection,
poor wound healing and chronic pain. We also provided in-
formation on average timescales, as even when the surgery
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and recovery go well, the process still takes many months,
with a reduction in quality of life during this period. We bal-
anced this with the obvious advantage of reducing the lifetime
breast cancer risk significantly, to less than 5%, with subse-
quent breast screening not required due to the minimal amount
of residual breast tissue.
We spent some time weighing the approximate 10% risk of
breast cancer over five years with an estimated 50–75%
chance of recurrent ovarian cancer over the same time period.
The aim of providing information in this context was to in-
crease the patient’s knowledge about breast cancer risk, as
well as potentially reducing breast cancer risk perception
and anxiety during the five year period of ovarian cancer
treatment and active follow up. Genetic counseling interven-
tions involved presenting the information in verbal and visual
format (numerical and graphical), checking understanding and
providing a designated time and space to focus on current
concerns. The patient did not appear anxious or distressed
by the information provided, but did express gratitude for
the opportunity to ask questions in a review appointment.
Towards the end of the session, she asked at what stage it
would be advisable to review the question about breast cancer
risk management and the suggestion of a review on request
five years after diagnosis was mutually agreed.
Case Report: Genetic Counseling Challenges
If and when risk-reducing breast surgery in BRCA1/BRCA2
carriers with a previous diagnosis of ovarian cancer is appro-
priate is not easily answered by current research evidence.
This is reflected by guidelines on breast cancer risk manage-
ment in BRCA1/BRCA2 carriers, which do not give clear rec-
ommendations for women with a previous diagnosis of ovar-
ian cancer, but support discussion of the option of risk-
reducing breast surgery with women on a case-by-case basis
(NCCN, 2016). Contraindications to risk-reducing breast sur-
gery are stated in the UK NICE guidelines as co-morbidities
that would considerably increase the risks of surgery or that
cause limited life expectancy (NICE 2013). Uncertainty about
recurrence of ovarian cancer featured prominently in the ge-
netic counseling we provided. In discussing this, we were
aware of blurring boundaries between the role of clinical ge-
netics and oncology. Fortunately, we had support and close
liaison with the patient’s oncology team and this case
highlighted the benefits of the multi-disciplinary approach.
The chance of surviving ovarian cancer increases with the
number of recurrence-free years post diagnosis (Narod 2016).
The figures used in our genetic counseling case were mainly
risks over a five-year period. Five-year risks are often used in
genetic counseling for BRCA1/BRCA2 carriers, due to the
available data from relevant research studies. Five-year risks
were also chosen for genetic counseling in this case in order to
answer the patient’s questions addressing risk management in
the short- to medium-term. In our case report, a fuller discus-
sion on the potential risks and benefits of risk-reducing breast
surgery took place almost three years after ovarian cancer
diagnosis without signs of recurrence. In this situation, it
may be more appropriate to consider the impact on the
risk/benefit ratio at the ten-year mark. Ten years after ovarian
cancer diagnosis there is less uncertainty about the chance of
relapse, which is significantly reduced (Narod 2016).
However, ten years after ovarian cancer diagnosis, our patient
will be age 64 years, at which point her remaining lifetime risk
of breast cancer will be smaller and the risks associated with
any surgery will be increased. From a genetic counselor’s
perspective, discussing ten year risks in the initial years after
a diagnosis of ovarian cancer may not best answer their pa-
tients’ questions, given the poor overall survival and need for
a shorter-term plan for breast cancer risk management.
When providing genetic counseling to women with
ovarian cancer and a recently identified BRCA1/BRCA2
mutation, genetic counselors have breast cancer risk man-
agement on their agenda. Who raises this issue and when
it is raised during the consultation depends on many fac-
tors, which may include the patient’s pre-test understand-
ing of BRCA1/BRCA2 mutation risks, family history and
response to ovarian cancer treatment. In the case de-
scribed here, information on breast cancer risk manage-
ment options, including risk-reducing strategies, were pre-
sented in general terms. In this way, risk-reducing surgery
was raised as having been proven to reduce breast cancer
risk in BRCA1/BRCA2 carriers, but also as something not
usually considered when the focus is on ovarian cancer
treatment. For women who have an excellent response to
treatment and are well two to three years later, there is
potential for a mismatch between what a genetic counsel-
or perceives as a remaining focus on ovarian cancer and
how a patient views this, whilst being told there are no
signs of relapse at regular oncology reviews. For many
women, who are not interested in risk-reducing mastecto-
my, further genetic counseling to address this time-
sensitive issue may not be required. For those interested
in risk-reducing mastectomy, review is needed to provide
updated information on the potential risks and benefits, as
well to provide psychosocial support in decision making.
Part of the genetic counseling acknowledged the impor-
tance of hope and optimism as strategies for coping with un-
certainty. There is evidence to show that fear of ovarian cancer
recurrence is linked to reduced levels of hope (Ozga et al.
2015) and that hope is an important factor for women in en-
abling them to face the threat of ovarian cancer recurrence
after completion of first-line treatment (Reb 2007). Hope
and optimism have also been found as facilitating adaptation
to an increased familial breast cancer risk, when this has been
studied in women from high-risk families with and without a
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BRCA1/BRCA2 mutation (Heiniger et al. 2015). We tried to
sustain hope by checking how much information the patient
wanted about risks of ovarian cancer recurrence, whilst ac-
knowledging the limitations of presenting data that cannot
accurately predict an individual’s future. Checking informa-
tion preferences, alongside an awareness of and empathy for
the potential impact of the information provided are commu-
nication skills integral to genetic counseling.
Considerations for Genetic Counseling Practice
Following the identification of a BRCA1/BRCA2 mutation
shortly after ovarian cancer diagnosis, the initial focus is often
placed on treatment implications for the woman and risks to her
relatives. This report highlights the genetic counseling needs of
the index case and shows how these needs can change over
time. Genetic counseling for women with ongoing questions
about breast cancer risk management is time sensitive and is
influenced by the number of years since ovarian cancer diag-
nosis. Who initiates genetic counseling review will depend on
various factors, including if the clinical genetics center has a
regular recall system for BRCA1/BRCA2 carriers. In the ab-
sence of systematic follow up, genetic counselors should seek
to empower patients at every opportunity, so that they willingly
seek further genetic counseling input as required.
The provision of genetic counseling described was
aided by a supportive relationship with oncology col-
leagues. As genetic testing becomes integrated into the
routine management of individuals with ovarian cancer,
more women with a germline BRCA1/BRCA2 mutation
will be identified. Open and supportive dialogue between
clinical genetics and oncology health professionals is
likely to have patient benefits. For women with ovarian
cancer and a BRCA1/BRCA2 germline mutation who are
interested in risk-reducing breast surgery, realistic infor-
mation should be presented in an individualized way, in
order to facilitate women making decisions about their
own life and body. Individual factors in this situation
will include tumor stage, time since diagnosis, current
health, age, patient breast cancer risk perception and risk
management preferences. This involves a careful balance
of providing complex risk information whilst taking into
account the information and emotional needs of the in-
dividual. Clinical genetics professionals are well placed
to provide this service. Qualitative research to evaluate
how women adapt to and view BRCA1/BRCA2-related
breast cancer risk after ovarian cancer could further in-
form genetic counseling practice. Longer term quantita-
tive studies are also needed to provide information about
breast cancer risk to women with a BRCA1/BRCA2 mu-
tation who are disease-free more than five years after
treatment for ovarian cancer.
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